[go: up one dir, main page]

GT199700075A - Analogos de indazol sustituido - Google Patents

Analogos de indazol sustituido

Info

Publication number
GT199700075A
GT199700075A GT199700075A GT199700075A GT199700075A GT 199700075 A GT199700075 A GT 199700075A GT 199700075 A GT199700075 A GT 199700075A GT 199700075 A GT199700075 A GT 199700075A GT 199700075 A GT199700075 A GT 199700075A
Authority
GT
Guatemala
Prior art keywords
replaced
indazole analogs
analogs
indazole
indazol
Prior art date
Application number
GT199700075A
Other languages
English (en)
Inventor
Anthony Marfat
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of GT199700075A publication Critical patent/GT199700075A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4151,2-Diazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

ESTA INVENCION SE REFIERE A NUEVOS ANALOGOS DE INDAZOL. LOS COMPUESTOS SON INHIBIDORES SELECTIVOS DE LA FOSFODIESTERASA (PDE) TIPO IV Y DE LA PRODUCCION DE FACTOR DE NECROSIS TUMORAL (TNF) Y COMO TALES SON UTILES EN EL TRATAMIENTO DEL ASMA, LA ARTRITIS, BRONQUITIS, ENFERMEDAD OBSTRUCTIVA CRONICA DE LAS VIAS RESPIRATORIAS, PSORIASIS, RINITIS ALERGICA, DERMATITIS Y OTRAS ENFERMEDADES INFLAMATORIAS, TRASTORNOS DEL SISTEMA NERVIOSO.
GT199700075A 1996-06-25 1997-06-12 Analogos de indazol sustituido GT199700075A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US2038596P 1996-06-25 1996-06-25

Publications (1)

Publication Number Publication Date
GT199700075A true GT199700075A (es) 1998-12-04

Family

ID=21798354

Family Applications (1)

Application Number Title Priority Date Filing Date
GT199700075A GT199700075A (es) 1996-06-25 1997-06-12 Analogos de indazol sustituido

Country Status (43)

Country Link
US (1) US6040329A (es)
EP (1) EP0912558B1 (es)
JP (1) JP3152940B2 (es)
KR (1) KR20000022516A (es)
CN (1) CN1080260C (es)
AP (1) AP1025A (es)
AR (1) AR007456A1 (es)
AT (1) ATE244713T1 (es)
AU (1) AU716376B2 (es)
BG (1) BG64052B1 (es)
BR (1) BR9712782A (es)
CA (1) CA2258285C (es)
CO (1) CO4900056A1 (es)
CZ (1) CZ423398A3 (es)
DE (1) DE69723447T2 (es)
DK (1) DK0912558T3 (es)
DZ (1) DZ2254A1 (es)
EA (1) EA002274B1 (es)
ES (1) ES2201299T3 (es)
GT (1) GT199700075A (es)
HK (1) HK1018700A1 (es)
HN (1) HN1997000079A (es)
HR (1) HRP970350B1 (es)
HU (1) HUP9903009A3 (es)
ID (1) ID18579A (es)
IL (1) IL127036A (es)
IS (1) IS4910A (es)
MA (1) MA24225A1 (es)
MY (1) MY116915A (es)
NO (1) NO986103D0 (es)
NZ (1) NZ332752A (es)
OA (1) OA10934A (es)
PA (1) PA8432301A1 (es)
PL (1) PL330974A1 (es)
PT (1) PT912558E (es)
SI (1) SI0912558T1 (es)
SK (1) SK176598A3 (es)
TN (1) TNSN97108A1 (es)
TR (1) TR199802685T2 (es)
TW (1) TW434237B (es)
WO (1) WO1997049702A1 (es)
YU (1) YU60198A (es)
ZA (1) ZA975581B (es)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3102697A (en) 1996-06-19 1998-01-07 Rhone-Poulenc Rorer Limited Substituted azabicylic compounds and their use as inhibitors of the production of tnf and cyclic amp phosphodiesterase
IL128642A0 (en) * 1996-09-04 2000-01-31 Pfizer Indazole derivatives and their use as inhibitors of phosphodiesterase (pde) type iv and the production of tumor necrosis factor (tnf)
US6248746B1 (en) 1998-01-07 2001-06-19 Euro-Celtique S.A. 3-(arylalkyl) xanthines
EA200000385A1 (ru) * 1997-11-04 2000-10-30 Пфайзер Продактс Инк. Терапевтически активные соединения на основе индазольной биоизостерической замены катехина в ингибиторах фосфодиэстеразы типа vi (pde4)
BR9813926A (pt) * 1997-11-04 2000-09-19 Pfizer Prod Inc Substituição de bioisóstero de catecol por indazol em compostos terapeuticamente ativos
US6362213B1 (en) 1999-12-23 2002-03-26 Icos Corporation Cyclic AMP-specific phosphodiesterase inhibitors
WO2001047915A1 (en) * 1999-12-23 2001-07-05 Icos Corporation Cyclic amp-specific phosphodiesterase inhibitors
US6953774B2 (en) 2000-08-11 2005-10-11 Applied Research Systems Ars Holding N.V. Methods of inducing ovulation
US7205320B2 (en) 2001-01-22 2007-04-17 Memory Pharmaceuticals Corp. Phosphodiesterase 4 inhibitors
US7153871B2 (en) 2001-01-22 2006-12-26 Memory Pharmaceuticals Corporation Phosphodiesterase 4 inhibitors, including aminoindazole and aminobenzofuran analogs
JP4535680B2 (ja) * 2001-04-16 2010-09-01 エーザイ・アール・アンド・ディー・マネジメント株式会社 新規1h−インダゾール化合物
DK1908463T3 (da) 2001-12-14 2011-11-28 Merck Serono Sa Fremgangsmåder til at inducere ægløsning ved anvendelse af en ikke polypeptid-CAMP-niveaumodulator
WO2004009552A1 (en) 2002-07-19 2004-01-29 Memory Pharmaceuticals Corporation Phosphodiesterase 4 inhibitors, including n-substituted aniline and diphenylamine analogs
RU2354648C2 (ru) * 2002-07-19 2009-05-10 Мемори Фармасьютиклз Корпорейшн Соединения 6-амино-1н-индазола и 4-аминобензофурана в качестве ингибиторов фосфодиэстеразы 4
EP1569908B1 (en) 2002-11-19 2010-09-15 Memory Pharmaceuticals Corporation Pyridine n-oxide compounds as phosphodiesterase 4 inhibitors
US7226930B2 (en) * 2003-04-18 2007-06-05 Memory Pharmaceutical Corporation Phosphodiesterase 4 inhibitors
US20090048255A1 (en) * 2003-07-21 2009-02-19 Schumacher Richard A Phosphodiesterase 4 inhibitors, including n-substituted aniline and diphenylamine analogs
MY141255A (en) * 2003-12-11 2010-03-31 Memory Pharm Corp Phosphodiesterase 4 inhibitors, including n-substituted diarylamine analogs
CN101166733A (zh) 2004-10-15 2008-04-23 记忆药物公司 作为磷酸二酯酶4抑制剂的吡唑衍生物
US7601847B2 (en) 2004-10-26 2009-10-13 Wyeth Preparation and purification of 4-(indazol-3-yl)phenols
WO2006129158A2 (en) * 2005-05-30 2006-12-07 Ranbaxy Laboratories Limited 3 - indazolyl - isoxazoline derivatives as inhibitors of phosphodiesterase type - i
EP2258359A3 (en) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenesis by muscarinic receptor modulation with sabcomelin
EP1928437A2 (en) 2005-08-26 2008-06-11 Braincells, Inc. Neurogenesis by muscarinic receptor modulation
EP1928866A1 (en) * 2005-09-05 2008-06-11 Ranbaxy Laboratories Limited Substituted indazoles as inhibitors of phosphodiesterase type-iv
WO2007031838A1 (en) 2005-09-16 2007-03-22 Ranbaxy Laboratories Limited Substituted pyrazolo [3,4-b] pyridines as phosphodiesterase inhibitors
JP2009512711A (ja) 2005-10-21 2009-03-26 ブレインセルス,インコーポレイティド Pde阻害による神経新生の調節
AU2006308889A1 (en) 2005-10-31 2007-05-10 Braincells, Inc. GABA receptor mediated modulation of neurogenesis
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
EP2021000A2 (en) 2006-05-09 2009-02-11 Braincells, Inc. Neurogenesis by modulating angiotensin
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
CN103497185A (zh) 2007-03-14 2014-01-08 兰贝克赛实验室有限公司 用作磷酸二酯酶抑制剂的吡唑并(3,4-b)吡啶衍生物
WO2010003084A2 (en) * 2008-07-02 2010-01-07 Memory Pharmaceuticals Corporation Phosphodiesterase 4 inhibitors
WO2010099217A1 (en) 2009-02-25 2010-09-02 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
AU2010311511B2 (en) * 2009-10-30 2014-07-17 Janssen Pharmaceutica Nv Imidazo[1,2-b]pyridazine derivatives and their use as PDE10 inhibitors
US20150119399A1 (en) 2012-01-10 2015-04-30 President And Fellows Of Harvard College Beta-cell replication promoting compounds and methods of their use
US20150125438A1 (en) * 2012-07-20 2015-05-07 Sang Jae Kim Anti-Inflammatory Peptides and Composition Comprising the Same
US9856263B2 (en) 2014-04-28 2018-01-02 Pfizer Inc. Heteroaromatic compounds and their use as dopamine D1 ligands
KR20220167804A (ko) * 2021-06-11 2022-12-22 주식회사 메타센테라퓨틱스 인돌 유도체를 포함하는 최종당화산물 관련 질환의 치료용 조성물
KR20220167441A (ko) * 2021-06-11 2022-12-21 주식회사 메타센테라퓨틱스 신규한 인돌 유도체 및 이의 최종당화산물 관련 질환의 치료 용도

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB753573A (en) * 1953-06-17 1956-07-25 Ici Ltd New dyestuffs intermediates
GB8707051D0 (en) * 1986-04-15 1987-04-29 Ici America Inc Heterocyclic carboxamides
PT100441A (pt) * 1991-05-02 1993-09-30 Smithkline Beecham Corp Pirrolidinonas, seu processo de preparacao, composicoes farmaceuticas que as contem e uso
TW223004B (es) * 1991-11-25 1994-05-01 Sumitomo Chemical Co
US5444038A (en) * 1992-03-09 1995-08-22 Zeneca Limited Arylindazoles and their use as herbicides
AU677776B2 (en) * 1992-04-02 1997-05-08 Smithkline Beecham Corporation Compounds useful for treating allergic and inflammatory diseases
US5612360A (en) * 1992-06-03 1997-03-18 Eli Lilly And Company Angiotensin II antagonists
US5554620A (en) * 1993-09-14 1996-09-10 Sterling Winthrop Inc. Substituted 6,11-ethano-6,11-dihydrobenzo[b] quinolizinium salts and compositions and methods of use thereof
JPH07215952A (ja) * 1993-12-06 1995-08-15 Otsuka Pharmaceut Factory Inc カテコール誘導体
WO1996012720A1 (en) * 1994-10-20 1996-05-02 Pfizer Inc. Bicyclic tetrahydro pyrazolopyridines and their use as medicaments

Also Published As

Publication number Publication date
MA24225A1 (fr) 1997-12-31
EP0912558A1 (en) 1999-05-06
ID18579A (id) 1998-04-23
HRP970350A2 (en) 1998-06-30
ATE244713T1 (de) 2003-07-15
BG64052B1 (bg) 2003-11-28
US6040329A (en) 2000-03-21
TNSN97108A1 (fr) 2005-03-15
DE69723447D1 (de) 2003-08-14
IL127036A (en) 2001-06-14
EA199801047A1 (ru) 1999-06-24
JP3152940B2 (ja) 2001-04-03
MY116915A (en) 2004-04-30
CZ423398A3 (cs) 1999-12-15
CN1223651A (zh) 1999-07-21
PT912558E (pt) 2003-11-28
AP9701020A0 (en) 1997-07-31
TR199802685T2 (xx) 1999-03-22
CA2258285C (en) 2002-11-26
OA10934A (en) 2002-02-18
NO986103L (no) 1998-12-23
KR20000022516A (ko) 2000-04-25
SK176598A3 (en) 2000-06-12
DK0912558T3 (da) 2003-08-18
WO1997049702A1 (en) 1997-12-31
HK1018700A1 (en) 1999-12-30
CN1080260C (zh) 2002-03-06
ES2201299T3 (es) 2004-03-16
EP0912558B1 (en) 2003-07-09
TW434237B (en) 2001-05-16
CA2258285A1 (en) 1997-12-31
CO4900056A1 (es) 2000-03-27
AU716376B2 (en) 2000-02-24
NZ332752A (en) 2001-04-27
EA002274B1 (ru) 2002-02-28
BG103056A (en) 1999-10-29
DZ2254A1 (fr) 2002-12-18
PL330974A1 (en) 1999-06-21
HUP9903009A3 (en) 2002-01-28
SI0912558T1 (en) 2003-10-31
HUP9903009A2 (hu) 2000-05-28
IS4910A (is) 1998-11-27
DE69723447T2 (de) 2003-12-24
AP1025A (en) 2001-11-19
AR007456A1 (es) 1999-10-27
BR9712782A (pt) 1999-12-07
IL127036A0 (en) 1999-09-22
JPH11514668A (ja) 1999-12-14
NO986103D0 (no) 1998-12-23
PA8432301A1 (es) 1999-12-27
ZA975581B (en) 1998-12-24
AU2785797A (en) 1998-01-14
HN1997000079A (es) 1997-12-26
HRP970350B1 (en) 2003-04-30
YU60198A (sh) 1999-09-27

Similar Documents

Publication Publication Date Title
GT199700075A (es) Analogos de indazol sustituido
GT199700102A (es) Derivados de indazol.
GT199700043A (es) Derivados del indazol sustituidos y compuestos relacionados
ES2192192T3 (es) Dieteres de catecol como inhibidores selectivos de pde iv.
MX9405132A (es) Tetrahidro pirazolopiridinas biciclicas.
ECSP067057A (es) Nuevos derivados de piridazin-3(2h)-ona
CO2019006200A2 (es) Inhibidores de moléculas pequeñas de la familia de quinasas jak
CO4180606A1 (es) Compuestos de isoxazolina como agentes antiinflamatorios
CL2019001633A1 (es) Imidazol pirrol piridina como inhibidores de la familia jak de quinasas.
ECSP099042A (es) Ciclobuten-1,2-dionas 3,4-di-sustituidas como ligandos de receptores de quimiocinas cxc
CO6870032A2 (es) Nuevos compuestos inhibidores de la fosfodiesterasa tipo 10a
DE602004025504D1 (de) Bicyclische heterocyclische p-38-kinase-inhibitoren
GT199800058A (es) Derivados de nicotinamida.
CR10387A (es) Derivados de 6,7,8,9-tetrahidro-5h-pirimido[4,5-d]azepin-4-il] amina como moduladores del potencial transitorio de receptor vaillinoide 1 para el tratamiento de dolor
ECSP067058A (es) Nuevos derivados de piridazin-3(2h)-ona
DE60210805D1 (de) Substituierte indolizinähnliche verbindungen und ihre verwendung
ATE389636T1 (de) Substituierte pyridin- und pyridazinderivate und ihre pharmazeutische verwendung
CO2017000912A2 (es) Derivados de 2 -h indazol como inhibidores de kinasas dependientes de ciclinas (cdk) y usos terapeuticos de los mismos
ATE424402T1 (de) Imidazopyridinverbindungen
HK10797774A1 (en) Aryl ureas as kinase inhibitors
UY27199A1 (es) Nuevos compuestos antiinflamatorios de triazolopiridinas
NZ727358A (en) Indazole inhibitors of the wnt signal pathway and therapeutic uses thereof
NO20073958L (no) Pyrrolidylderivater av heteroaromatiske forbindelser som fosfodiesteraseinhibitorer
HN1999000130A (es) 1-aril-3-arilmetil-1,8-naftiridin-4(1h)-onas.
ATE320426T1 (de) Harnstoffderivate und ihre verwendung